The second stage has been conducted by the university andthe Ho Chi Minh City-based Pasteur Institute since February 26. It has beencarried out at the university in Hanoi and the medical centre of Ben Lucdistrict in the southern province of Long An, with the participation of 560volunteers aged from 12-75, including 80 aged over 60.
They will receive two doses of either the vaccine or theplacebo AIPO4, with an interval of 28 days. Each volunteer will be monitoredfor 12 months after the first dose.
Volunteers receiving shots on the morning of February 26will receive the second doses in late March.
Lieutenant-General Do Quyet, Director of the MilitaryMedical University, said since the trial sees the participation of volunteerswith underlying health conditions, competent authorities have been prepared forall scenarios and ensure safety for all volunteers.
Results of the trial will be announced in May 2021 beforepreparing for the third-stage trial during which only one single shot of thevaccine will be administered to 10,000-15,000 people from both domestic andforeign pandemic-hit regions, Quyet added.
Developed by the Nanogen Pharmaceutical Biotechnology JSCand the Hanoi-based Military Medical University, Nano Covax is Vietnam’s firstCOVID-19 vaccine to reach the human trial stage.
The first-stage trial of the Nano Covax vaccine showed thatit is likely to be effective against the B117 variant from the UK.
Vietnam is one of 40 countries and territories in the worldto have begun human trials of a COVID-19 vaccine, after successfully producingcoronavirus test kits early in the pandemic./.